FDA cites firms for CGMP violations, unapproved products, and device reporting issues
Regulatory NewsFerdous Al-Faruque
CDERCDRHMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)Warning letters